DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA. Applicants’ amendment to the claims filed on 2/10/2026 is acknowledged. This listing of claims replaces all prior listings of claims in the application. Claims 1-17 are pending. Election/Restrictions Applicant’s election without traverse of Group I (claims 1-8, 11-17) in the reply filed on 2/10/2026 is acknowledged. Claims 1- 20 are pending. Claims 9-10, 18-20 stands withdrawn pursuant to 37 CFR 1.142(b). Claims 1-8, 11-17 are pending and examined on the merits. Priority Acknowledgement is made of this national stage entry of PCT/CN2022/140536 filed on 12/21/2022, which claims foreign priority to Chinese Patent Application Number CN202211064221,6, filed on 9/1/2022. The certified copy has been filed in the present application on 2/10/2026 . Information Disclosure Statement The information disclosure statement (IDS) submitted on 3/5/2025, 7/14/2025, 12/15/2025 is acknowledged. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement has been considered by the examiner. Drawings The Drawings filed on 10/25/2023 are acknowledged and accepted by the examiner. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b ) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the appl icant regards as his invention. Claim s 7, 8 , 15, 16 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 7 recites the limitation s " the polypeptide Cm and the polypeptide Zmb ” (in lines 7-8). There is insufficient antecedent basis for this limitation in the claim. Appropriate correction is suggested. Regarding claim s 7 , 15, 16 , the phrase " t he fusion-type multimeric protein comprises 4 polypeptides Cm, 1 functional polypeptide FLD and 2 polypeptides Zmb sequentially from N-terminal to C- terminal " renders the claim indefinite because it is unclear whether the limitations following the phrase are part of the claimed invention. It is unclear if the claim encompasses the claimed polypeptide in claims 1, 4, of which claim 7 dependents or a different polypeptide. It is suggested that Applicant amend the claim to ‘t he fusion-type multimeric protein further comprises 4 polypeptides Cm, 1 functional polypeptide FLD and 2 polypeptides Zmb sequentially from N-terminal to C- terminal .’ Appropriate correction is suggested. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis ( i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale , or otherwise available to the public before the effective filing date of the claimed invention. Claims 1, 2, 3, 4, 5, 6, 8, 11, 12, 13, 14, 17 are rejected under 35 U.S.C. 102 a1 as being anticipated by JP2006304633A (Date of Publication: 2006-11-09, cited on IDS dated 3/5/2025) {herein ‘633A} . Claims 1-3, 11-13 are drawn to a polypeptide, wherein the polypeptide is selected from: (1) a polypeptide having a substitution mutation in at least one position selected from the group consisting of positions 16, 25, 29, 49 and 58, as compared with a natural C structural domain of a protein A as shown in SEQ ID NO.1; wherein, the position 16 is subjected to a substitution mutation into leucine or valine; the position 25 is subjected to a substitution mutation into lysine, arginine, histidine or tryptophan; the position 29 is subjected to a substitution mutation into alanine, leucine or threonine; the position 49 is subjected to a substitution mutation into arginine or histidine; and the position 58 is subjected to a substitution mutation into glycine, isoleucine or alanine; or (2) a polypeptide having at least 80% of sequence identity to the polypeptide in (1) and retaining substitution mutation in at least one position selected from the group consisting of positions 16, 25, 29, 49 and 58. Claims 4-7 , 14 -16 are drawn to a fusion-type multimeric protein, wherein the fusion-type multimeric protein comprises the fusion-type multimeric protein formed by fusion of the polypeptide according to any one of claim 1. Claim 8 is drawn to a biomaterial, wherein the biomaterial comprises any of the following: 1) a nucleic acid molecule encoding the polypeptide according to claim 1; optionally, the nucleic acid molecule is DNA or RNA; 2) an expression cassette, a recombinant vector, a recombinant microorganism or a transgenic cell line expressing the polypeptide according to claim 1; 3) an expression cassette, a recombinant vector, a recombinant microorganism or a transgenic cell line containing the nucleic acid molecule described in 1); 3) an expression cassette, a recombinant vector, a recombinant microorganism or a transgenic cell line containing the nucleic acid molecule described in 1); 4) a recombinant vector, recombinant microorganism or transgenic cell line containing the expression cassette described in 2) or 3); and 5) a host cell containing the recombinant vector described in 2) or 3) or 4);optionally, the recombinant vector is constructed from the Escherichia coli expression vector pET-30a(+); optionally, the host cell is Escherichia coli, and optionally, the Escherichia coli is Escherichia coli BL21(DE3). Claim 17 is drawn to a biomaterial, wherein the biomaterial comprises any of the following: 1) a nucleic acid molecule encoding the fusion-type multimeric protein according to claim 4; optionally, the nucleic acid molecule is DNA or RNA; 2) an expression cassette, a recombinant vector, a recombinant microorganism or a transgenic cell line expressing the fusion-type multimeric protein according to claim 4; 3) an expression cassette, a recombinant vector, a recombinant microorganism or a transgenic cell line containing the nucleic acid molecule described in 1); 4) a recombinant vector, recombinant microorganism or transgenic cell line containing the expression cassette described in 2) or 3); and 5) a host cell containing the recombinant vector described in 2) or 3) or 4); optionally, the recombinant vector is constructed from the Escherichia coli expression vector pET-30a(+); optionally, the host cell is Escherichia coli, and optionally, the Escherichia coli is Escherichia coli BL21(DE3). With respect to claims 1, 2, 3, 4, 5 , 6, 8, 11, 12, 13, 14, 17 ‘633A teaches a C domain multimeric polypeptide of Staphylococcus protein A that is modified with a substitution at G29A (appendix A; page 3, para 5; page 4, para 1) and position 16 (page 3, para 4). Said polypeptide is encoded by a nucleic acid (page 4, para 1) of which can be utilized within an affinity column for characterization of samples via the multimeric protein (page 4, para 1) , of which is comprised of 2 or more immunoglobulin-binding domains that are linked (page 7, para 3) . Absent evidence otherwise, it is the Examiner’s position that the affinity column of which contains the multimeric protein encoded by nucleic acid is a biomaterial as it utilizes immobilized biological molecules to bind and purify target biomolecules. Additionally, it is the Examiner’s position that said multimeric domain taught by ‘633A is the designated polypeptide Cm as Applicant defines polypeptide Cm as being comprised of polypeptide B (instant application SEQ ID NO: 2; appendix B) fusion-type multimeric protein (instant application claims 6, 14). Additionally, it is noted that Applicant has not included a SEQ ID NO for polypeptide Cm within the instant application claims and specification. Furthermore, ‘633A teaches t he G29A polypeptide (appendix A) is cloned into a pET vector for synthesis of a C-G29A fusion protein (page 9, para 3). The C-G29A fusion protein immunoglobulin binding domain portion corresponds to SEQ ID NO: 2 , which is the same as the instant application SEQ ID NO: 1 ( appendix A ). Furthermore, ‘633A teaches an equifunctional variant of the Z domain (Z domain in which the 1-position of the Z domain was replaced with Ala; Z-V1A) was cloned into a pET vector, effectively resulting in a Z-VIA fusion protein which is the same as SEQ ID NO: 2 of the instant application (page 9, para 2 and para 3; appendix B ). For the reasons stated herein, the teachings of ‘633A anticipates claims 1, 2, 3, 4, 5, 6, 8, 11, 12, 13, 14, 17 . Conclusion Status of Claims Claims 1- 20 are pending. Claims 9-10, 18-20 stands withdrawn pursuant to 37 CFR 1.142(b). Claims 1-8, 11-17 are rejected. No claims are in condition for allowance. Any inquiry concerning this communication or earlier communications from the examiner should be directed to FILLIN "Examiner name" \* MERGEFORMAT ERICA NICOLE JONES-FOSTER whose telephone number is FILLIN "Phone number" \* MERGEFORMAT (571)270-0360 . The examiner can normally be reached FILLIN "Work Schedule?" \* MERGEFORMAT mf 7:30a - 4:30p . Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, FILLIN "SPE Name?" \* MERGEFORMAT Manjunath Rao can be reached at FILLIN "SPE Phone?" \* MERGEFORMAT 571-272-0939 . The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ERICA NICOLE JONES-FOSTER/ Examiner, Art Unit 1656 /MANJUNATH N RAO/ Supervisory Patent Examiner, Art Unit 1656 Appendix A ‘633A SEQ ID NO: 2 vs Instant application seq id no: 1 (G29A) Query Match 98.0%; Score 290; Length 58; Best Local Similarity 98.3%; Matches 57; Conservative 0; Mismatches 1; Indels 0; Gaps 0; Qy 1 ADNKFNKEQQNAFYEILHLPNLTEEQRN G FIQSLKDDPSVSKEILAEAKKLNDAQAPK 58 Db 1 ADNKFNKEQQNAFYEILHLPNLTEEQRN A FIQSLKDDPSVSKEILAEAKKLNDAQAPK 58 Appendix B ‘633A SEQ ID NO: 1 (polypeptide B) vs Instant application SEQ ID NO: 2 Query Match 98.0%; Score 292; Length 58; Best Local Similarity 98.3%; Matches 57; Conservative 0; Mismatches 1; Indels 0; Gaps 0; Qy 1 ADNKFNKEQQNAFYEILHLPNLNEEQRNGFIQSLKDDPSQSANLLAEAKKLNDAQAPK 58 Db 1 ADNKFNKEQQNAFYEILHLPNLNEEQRNAFIQSLKDDPSQSANLLAEAKKLNDAQAPK 58